FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment

1. FDA approves Spravato as standalone treatment for major depressive disorder. 2. Spravato shows rapid effect; $780 million sales in the first nine months of 2024. 3. Potential annual sales could reach $1-5 billion, enhancing JNJ's revenue outlook. 4. One-third of 21 million U.S. adults may benefit from this new option. 5. J&J's growing confidence in Spravato results from five years of real-world data.